Hypertension,Essential Clinical Trial
— IMPROVEHOfficial title:
Impact of Aerobic Exercise Training on Sympathetically Mediated Vasoconstriction and Vascular Function in Individuals With Essential Hypertension (IMPROVEH)
Verified date | November 2022 |
Source | University of Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sympathetic nervous activity plays an important role in the development of hypertension and studies have shown that the pannexin-1 channel is involved in the signalling of the sympathetic activity to the vascular bed. The main project aim is to investigate the effects of 10 weeks of high intensity training on the effect of the sympathetic nervous activity on vascular function in individuals with essential hypertension. A secondary aim is to assess the role of essential hypertension and physical activity on vascular endothelial function,
Status | Completed |
Enrollment | 30 |
Est. completion date | November 1, 2022 |
Est. primary completion date | November 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 35 Years to 65 Years |
Eligibility | Inclusion Criteria: - Sedentary men and women age 35 - 65 years - Resting blood pressure >140/90 mmHg or Resting blood pressure <140/90 mmHg - Essential hypertension - Non or exclusively antihypertensive medication Exclusion Criteria: - Hypertensive condition other than essential hypertension - Other chronical diseases - Smoking - Excess alcohol intake or drug abuse |
Country | Name | City | State |
---|---|---|---|
Denmark | University of Copenhagen | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
University of Copenhagen | Danish Council for Independent Research, Lundbeck Foundation |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood pressure | Changes in systolic and diastolic blood pressure | Before and after 8 weeks of training | |
Secondary | Pannexin channel function assessed in vivo | Pannexin channel function is assessed by measurement of vascular conductance with and without channel inhibition | Before and after 8 weeks of training | |
Secondary | Pannexin channel distribution in skeletal muscle tissue | Pannexin channel distribution is assessed immunohistochemically in muscle samples | Before and after 8 weeks of training | |
Secondary | Sympathetic activity | Direct measurement of Muscle Sympathetic Nervous Activity via microneurography | Before and after 8 weeks of training | |
Secondary | Vascular function | Vascular conductance measured by ultrasound doppler during infusion of vasoactive substances | Before and after 8 weeks of training | |
Secondary | Mitochondrial function in endothelial cells | Endothelial cell mitochondrial respiration is measured by High Resolution Respirometry | Before and after 8 weeks of training | |
Secondary | Reactive oxygen species formation in in endothelial cells | Endothelial cell production of reactive oxygen species is measured by High Resolution Respirometry | Before and after 8 weeks of training | |
Secondary | Rheology | Platelet rheology. The viscoelastic measurements are based on attainment of the Gel Point (GP) from which the fractal dimension, df, is determined. | Before and after 8 weeks of training | |
Secondary | Platelet reactivity | Platelet reactivity is assessed by multiplate aggregometry | Before and after 8 weeks of training | |
Secondary | Maximal oxygen uptake | Direct Measurement of oxygen uptake during a graded test on cycle ergometer | Before and after 8 weeks of training | |
Secondary | Body Composition | Measured by Dual energy x-ray absorptiometry | Before and after 8 weeks of training | |
Secondary | Endothelial cell characterization | Assessment of protein and mRNA-levels of proteins of relevance for endothelial function | Before and after 8 weeks of training | |
Secondary | Skeletal muscle characterization | Assessment of protein and mRNA-levels of proteins of relevance for skeletal muscle function | Before and after 8 weeks of training |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05546931 -
Mobile Health Program for Rural Hypertension
|
N/A | |
Completed |
NCT05086549 -
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
|
||
Recruiting |
NCT05086523 -
Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03503773 -
The TARGET BP OFF-MED Trial
|
Phase 2 | |
Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
Recruiting |
NCT06019598 -
Licorice and Home Blood Pressure, Additional Study
|
N/A | |
Completed |
NCT04495231 -
Sympathetic Activity and Cardiometabolic Complications
|
||
Completed |
NCT04119999 -
A Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling
|
N/A | |
Recruiting |
NCT04505618 -
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
|
N/A | |
Recruiting |
NCT04863508 -
Wearable Blood Pressure Devices to Identify Masked Uncontrolled Hypertension.
|
||
Completed |
NCT05185297 -
Recreational Futsal for Controlled Hypertension
|
N/A | |
Completed |
NCT03855605 -
Diagnosis of Hypertension by Home Blood Pressure Monitoring
|
||
Completed |
NCT03901183 -
Plant-based Nutrition for Patients With Cardiovascular Risk Factors
|
N/A | |
Recruiting |
NCT06348576 -
Phase III Study to Evaluate the Efficacy and Safety of AD-209
|
Phase 3 | |
Recruiting |
NCT03206814 -
Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System
|
N/A | |
Recruiting |
NCT06343246 -
Functional Inspiratory Muscle Training in Patients Diagnosed With Hypertension
|
N/A | |
Completed |
NCT06359873 -
Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension
|
||
Recruiting |
NCT04565548 -
Hypertension Treatment Adherence Improving Trial
|
N/A | |
Recruiting |
NCT06205628 -
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
|
Phase 1 | |
Recruiting |
NCT04613193 -
Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis
|
N/A |